BamSEC and AlphaSense Join Forces
Learn More

Avalo Therapeutics Inc. – Underwriting Agreements

NASDAQ: AVTX    
Share price (6/2/26): $13.96    
Market cap (6/2/26): $734 million
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1.1
from 8-K 47 pages 19,730,000 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 1,400,000 Shares of Common Stock Avalo Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 41 pages Avalo Therapeutics, Inc. Common Stock Sales Agreement
12/34/56
EX-1.1
from 8-K 2 pages Amendment No. 1 to Sales Agreement August 7, 2023
12/34/56
EX-1.1
from 8-K 6 pages Avalo Therapeutics, Inc. Shares of Common Stock ($0.001 Par Value Per Share) Sales Agreement
12/34/56
EX-1.1
from 8-K 36 pages 3,770,000 Shares 3,770,000 Warrants to Purchase 3,770,000 Shares Avalo Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 44 pages 12,500,000 Shares Avalo Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 37 pages Cerecor Inc. Shares of Common Stock (Par Value $0.001 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-1.1
from 8-K 45 pages 12,323,077 Shares Pre-Funded Warrants to Purchase 1,676,923 Shares Cerecor Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 38 pages 13,200,000 Shares Cerecor Inc. Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 38 pages 1,818,182 Shares of Common Stock of Cerecor Inc. Amended and Restated Underwriting Agreement
12/34/56
EX-1
from 8-K 5 pages Cerecor Inc. Reports Third Quarter 2017 Financial Results Current Cash and Escrowed Cash Receivables in Excess of $27 Million
12/34/56
EX-1.1
from S-1/A 82 pages Cerecor Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 53 pages Cerecor Inc. Underwriting Agreement
12/34/56